blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2219618

EP2219618 - PHARMACEUTICAL FORMULATIONS FOR THE ORAL ADMINISTRATION OF PPI [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  27.11.2015
Database last updated on 20.07.2024
Most recent event   Tooltip27.11.2015Application deemed to be withdrawnpublished on 30.12.2015  [2015/53]
Applicant(s)For all designated states
Valpharma S.A.
Via Ranco, 112
47899 Serravalle / SM
[2010/34]
Inventor(s)01 / VALDUCCI, Roberto
Via del Sole 4
I-47039 Savignano Sul Rubicone / IT
02 / ALIGHIERI, Tiziano
Via Casadei Flavia 24
I-47900 Rimini / IT
03 / AVANESSIAN, Serozh
Via Cesare Pavese 34
I-47827 Villa Verucchio / IT
 [2010/34]
Representative(s)Gervasi, Gemma, et al
Notarbartolo & Gervasi S.p.A.
Viale Achille Papa, 30
20149 Milano / IT
[N/P]
Former [2010/34]Gervasi, Gemma, et al
Notarbartolo & Gervasi S.p.A. Corso di Porta Vittoria 9
20122 Milano / IT
Application number, filing date08846855.807.11.2008
[2010/34]
WO2008EP65127
Priority number, dateIT2007FI0025309.11.2007         Original published format: IT FI20070253
[2010/34]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2009060064
Date:14.05.2009
Language:EN
[2009/20]
Type: A2 Application without search report 
No.:EP2219618
Date:25.08.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 14.05.2009 takes the place of the publication of the European patent application.
[2010/34]
Search report(s)International search report - published on:EP25.06.2009
ClassificationIPC:A61K9/20, A61K9/28, A61K31/44
[2010/34]
CPC:
A61K9/2826 (EP,US); A61K31/44 (EP,US); A61K9/2086 (EP,US);
A61K9/284 (EP,US); A61K9/2846 (EP,US); A61K9/2853 (EP,US);
A61K9/2886 (EP,US); A61P1/00 (EP); A61K9/2027 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/34]
TitleGerman:PHARMAZEUTISCHE FORMULIERUNGEN ZUR ORALEN VERABREICHUNG VON PPI[2010/34]
English:PHARMACEUTICAL FORMULATIONS FOR THE ORAL ADMINISTRATION OF PPI[2010/34]
French:FORMULATIONS PHARMACEUTIQUES POUR L'ADMINISTRATION PAR VOIE ORALE DE PPI[2010/34]
Entry into regional phase07.06.2010National basic fee paid 
07.06.2010Designation fee(s) paid 
07.06.2010Examination fee paid 
Examination procedure08.09.2009Request for preliminary examination filed
International Preliminary Examining Authority: EP
07.06.2010Amendment by applicant (claims and/or description)
07.06.2010Examination requested  [2010/34]
23.07.2012Despatch of a communication from the examining division (Time limit: M04)
23.11.2012Reply to a communication from the examining division
19.03.2015Despatch of a communication from the examining division (Time limit: M04)
30.07.2015Application deemed to be withdrawn, date of legal effect  [2015/53]
27.08.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2015/53]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.07.2012
Fees paidRenewal fee
15.10.2010Renewal fee patent year 03
07.10.2011Renewal fee patent year 04
08.10.2012Renewal fee patent year 05
04.09.2013Renewal fee patent year 06
10.11.2014Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]DE4437442  (VOSS GUNTHER MEINHARDT [DE]) [Y] 1-12* the whole document *;
 [XY]US2003228363  (PATEL MAHENDRA R [US], et al) [X] 1-4,10,11 * examples 1-11 * * page 1, paragraph 8 * [Y] 1-12;
 [X]US2005281876  (LI SHUN-POR [US], et al) [X] 1-3,11 * example 1 * * claims 1-18 *;
 [X]WO2006049565  (ASTRAZENECA AB [SE], et al) [X] 1-3,11 * example 1 * * claims 1-15 *;
 [X]EP1747776  (KRKA TOVARNA ZDRAVIL D D NOVO [SI]) [X] 1-4,10,11 * examples 1-8 * * claims 1-27 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.